文献速递神经MR

胶质瘤及邻近正常脑组织中的钆滞留:与肿瘤对比增强和线性/大环类对比剂的相关性

Gadolinium retention in gliomas and adjacent normal brain tissue: association with tumor contrast enhancement and linear/macrocyclic agents.
PubMed 文献 · Neuroradiology · 2019-02-02

这项回顾性研究纳入69例术前接受增强MRI的原发性胶质瘤患者,用ICP-MS定量肿瘤、正常脑组织和坏死标本中的钆沉积。结果显示57%肿瘤样本可检出钆,增强与非增强肿瘤均可检出,明显强化者钆含量最高(p=0.02);线性对比剂钆双胺和钆喷酸葡胺的肿瘤钆含量显著高于大环类钆特酸葡胺(分别p<0.01和p<0.05),多因素回归中对比剂类型是肿瘤钆滞留最强预测因子(p<0.001)。

要点

  • 57%(39/69)胶质瘤样本可检出钆,增强与非增强肿瘤均可检出。
  • 明显强化胶质瘤的钆含量最高(p=0.02)。
  • 线性对比剂钆双胺和钆喷酸葡胺的肿瘤钆含量显著高于大环类钆特酸葡胺。

核心结论

  • 增强和非增强胶质瘤、邻近正常脑组织及坏死组织中均可检出钆。
  • 暴露于线性钆对比剂后的钆滞留高于大环类钆特酸葡胺。

研究设计与样本

  • 回顾性研究,纳入69例术前接受增强MRI的原发性胶质瘤患者。
  • 采用电感耦合等离子体质谱(ICP-MS)定量组织学确认的存活肿瘤、正常脑组织和坏死标本中的钆。
  • 7例使用线性钆对比剂,62例使用大环类钆对比剂。

关键影像表现/征象

  • 肿瘤对比增强分为无、轻微和明显三类。
  • 钆沉积在39/69(57%)肿瘤样本、8/13(62%)正常脑组织和12/14(86%)坏死标本中检出。

诊断标准与关键数值

  • 肿瘤对比增强分级:无、轻微、明显。
  • 明显强化胶质瘤的钆含量最高(p=0.02)。
  • 线性钆双胺和大环类钆特酸葡胺的肿瘤钆含量比较p<0.01。
  • 线性钆喷酸葡胺和大环类钆特酸葡胺的肿瘤钆含量比较p<0.05。
  • 正常脑组织和坏死组织中,线性钆双胺暴露后的钆含量更高(均p<0.05)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To quantitate gadolinium deposits in gliomas and adjacent normal brain specimens, and to evaluate their association with tumor contrast enhancement and the type of gadolinium-based contrast agent (GBCA) used.

METHODS: A total of 69 patients with primary glioma who underwent contrast-enhanced magnetic resonance imaging (MRI) prior to surgery were included in this retrospective study. Gadolinium was measured from histologically viable tumor, normal brain, and necrosis within the sample, when available, using inductively coupled plasma mass spectrometry (ICP-MS). Tumor contrast enhancement was categorized as none, minimal, or noticeable. Differences in gadolinium deposits by contrast enhancement and GBCA type were assessed.

RESULTS: Seven patients received linear GBCA and 62 macrocyclic, respectively. At the time of surgery, gadolinium deposits were detected in 39 out of 69 (57%) tumor samples, 8 out of 13 (62%) normal brain, and 12 out of 14 (86%) necrotic specimens. Gadolinium was detected in both enhancing and non-enhancing tumors, but was greatest in gliomas with noticeable enhancement (p = 0.02). Administration of linear agents gadodiamide and gadopentetate dimeglumine resulted in significantly higher tumor gadolinium relative to macrocyclic gadoterate meglumine (p < 0.01 and p < 0.05, respectively). Normal brain and necrosis also showed higher gadolinium after exposure to linear gadodiamide (both p < 0.05). In multivariate regression, GBCA type (linear/macrocyclic) was the most powerful predictor of tumor gadolinium retention (p < 0.001).

CONCLUSION: Gadolinium can be detected in both enhancing and non-enhancing gliomas, neighboring normal brain, and necrosis. Gadolinium retention is higher after exposure to linear GBCAs compared with the macrocyclic gadoterate meglumine.

来源:Neuroradiology,查看原文。版权归原作者所有。

引用

  1. Kiviniemi A, Gardberg M, Ek P, et al. Gadolinium retention in gliomas and adjacent normal brain tissue: association with tumor contrast enhancement and linear/macrocyclic agents. Neuroradiology. 2019. PMID: 30710184. doi:10.1007/s00234-019-02172-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。